vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and HEALTHSTREAM INC (HSTM). Click either name above to swap in a different company.

HEALTHSTREAM INC is the larger business by last-quarter revenue ($79.7M vs $74.7M, roughly 1.1× Health Catalyst, Inc.). On growth, HEALTHSTREAM INC posted the faster year-over-year revenue change (7.4% vs -6.2%). HEALTHSTREAM INC produced more free cash flow last quarter ($13.0M vs $9.6M). Over the past eight quarters, HEALTHSTREAM INC's revenue compounded faster (4.7% CAGR vs -0.0%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

HealthStream Inc is a leading U.S.-based provider of workforce development, compliance, and training solutions tailored for the healthcare industry. It offers cloud-based platforms covering clinical skill training, talent management, patient safety education, and regulatory adherence tools, serving over 4,000 healthcare organizations including hospitals, clinics, and long-term care facilities nationwide.

HCAT vs HSTM — Head-to-Head

Bigger by revenue
HSTM
HSTM
1.1× larger
HSTM
$79.7M
$74.7M
HCAT
Growing faster (revenue YoY)
HSTM
HSTM
+13.6% gap
HSTM
7.4%
-6.2%
HCAT
More free cash flow
HSTM
HSTM
$3.3M more FCF
HSTM
$13.0M
$9.6M
HCAT
Faster 2-yr revenue CAGR
HSTM
HSTM
Annualised
HSTM
4.7%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HCAT
HCAT
HSTM
HSTM
Revenue
$74.7M
$79.7M
Net Profit
$-91.0M
Gross Margin
Operating Margin
-115.3%
3.0%
Net Margin
-121.9%
Revenue YoY
-6.2%
7.4%
Net Profit YoY
-340.3%
EPS (diluted)
$-1.29
$0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
HSTM
HSTM
Q4 25
$74.7M
$79.7M
Q3 25
$76.3M
$76.5M
Q2 25
$80.7M
$74.4M
Q1 25
$79.4M
$73.5M
Q4 24
$79.6M
$74.2M
Q3 24
$76.4M
$73.1M
Q2 24
$75.9M
$71.6M
Q1 24
$74.7M
$72.8M
Net Profit
HCAT
HCAT
HSTM
HSTM
Q4 25
$-91.0M
Q3 25
$-22.2M
$6.1M
Q2 25
$-41.0M
$5.4M
Q1 25
$-23.7M
$4.3M
Q4 24
$-20.7M
Q3 24
$-14.7M
$5.7M
Q2 24
$-13.5M
$4.2M
Q1 24
$-20.6M
$5.2M
Gross Margin
HCAT
HCAT
HSTM
HSTM
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
HCAT
HCAT
HSTM
HSTM
Q4 25
-115.3%
3.0%
Q3 25
-22.9%
9.9%
Q2 25
-46.0%
7.9%
Q1 25
-25.4%
6.0%
Q4 24
-22.0%
6.3%
Q3 24
-17.9%
8.9%
Q2 24
-20.8%
6.2%
Q1 24
-30.5%
7.8%
Net Margin
HCAT
HCAT
HSTM
HSTM
Q4 25
-121.9%
Q3 25
-29.1%
8.0%
Q2 25
-50.8%
7.2%
Q1 25
-29.9%
5.9%
Q4 24
-26.0%
Q3 24
-19.3%
7.8%
Q2 24
-17.8%
5.8%
Q1 24
-27.6%
7.2%
EPS (diluted)
HCAT
HCAT
HSTM
HSTM
Q4 25
$-1.29
$0.09
Q3 25
$-0.32
$0.20
Q2 25
$-0.59
$0.18
Q1 25
$-0.35
$0.14
Q4 24
$-0.33
$0.16
Q3 24
$-0.24
$0.19
Q2 24
$-0.23
$0.14
Q1 24
$-0.35
$0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
HSTM
HSTM
Cash + ST InvestmentsLiquidity on hand
$95.7M
$36.2M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$245.8M
$354.0M
Total Assets
$502.6M
$520.4M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
HSTM
HSTM
Q4 25
$95.7M
$36.2M
Q3 25
$91.5M
$53.5M
Q2 25
$97.3M
$52.1M
Q1 25
$342.0M
$77.3M
Q4 24
$392.0M
$59.5M
Q3 24
$387.3M
$57.5M
Q2 24
$308.3M
$46.1M
Q1 24
$327.8M
$52.4M
Total Debt
HCAT
HCAT
HSTM
HSTM
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
HCAT
HCAT
HSTM
HSTM
Q4 25
$245.8M
$354.0M
Q3 25
$331.9M
$349.2M
Q2 25
$347.5M
$350.6M
Q1 25
$376.8M
$362.8M
Q4 24
$365.2M
$359.4M
Q3 24
$355.0M
$355.5M
Q2 24
$357.0M
$349.2M
Q1 24
$357.2M
$344.9M
Total Assets
HCAT
HCAT
HSTM
HSTM
Q4 25
$502.6M
$520.4M
Q3 25
$587.1M
$499.9M
Q2 25
$616.2M
$500.1M
Q1 25
$891.5M
$524.0M
Q4 24
$858.9M
$510.8M
Q3 24
$813.0M
$502.8M
Q2 24
$691.7M
$499.6M
Q1 24
$695.1M
$511.6M
Debt / Equity
HCAT
HCAT
HSTM
HSTM
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
HSTM
HSTM
Operating Cash FlowLast quarter
$9.9M
$13.2M
Free Cash FlowOCF − Capex
$9.6M
$13.0M
FCF MarginFCF / Revenue
12.9%
16.3%
Capex IntensityCapex / Revenue
0.4%
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K
$59.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
HSTM
HSTM
Q4 25
$9.9M
$13.2M
Q3 25
$-464.0K
$18.0M
Q2 25
$-9.0M
$5.0M
Q1 25
$280.0K
$27.1M
Q4 24
$-3.5M
$11.2M
Q3 24
$6.2M
$19.1M
Q2 24
$1.6M
$6.5M
Q1 24
$10.3M
$20.9M
Free Cash Flow
HCAT
HCAT
HSTM
HSTM
Q4 25
$9.6M
$13.0M
Q3 25
$-719.0K
$17.9M
Q2 25
$-9.2M
$2.7M
Q1 25
$-390.0K
$26.0M
Q4 24
$-3.9M
$11.0M
Q3 24
$5.5M
$18.8M
Q2 24
$1.3M
$6.3M
Q1 24
$10.1M
$20.2M
FCF Margin
HCAT
HCAT
HSTM
HSTM
Q4 25
12.9%
16.3%
Q3 25
-0.9%
23.4%
Q2 25
-11.4%
3.6%
Q1 25
-0.5%
35.4%
Q4 24
-4.9%
14.8%
Q3 24
7.2%
25.8%
Q2 24
1.7%
8.8%
Q1 24
13.5%
27.8%
Capex Intensity
HCAT
HCAT
HSTM
HSTM
Q4 25
0.4%
0.3%
Q3 25
0.3%
0.1%
Q2 25
0.3%
3.1%
Q1 25
0.8%
1.4%
Q4 24
0.5%
0.3%
Q3 24
0.9%
0.4%
Q2 24
0.4%
0.2%
Q1 24
0.3%
1.0%
Cash Conversion
HCAT
HCAT
HSTM
HSTM
Q4 25
Q3 25
2.96×
Q2 25
0.93×
Q1 25
6.25×
Q4 24
Q3 24
3.34×
Q2 24
1.55×
Q1 24
4.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

HSTM
HSTM

Subscription Services$77.0M97%
Professional Services$2.7M3%

Related Comparisons